Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...

(NASDAQ: MYGN), a leader in genetic testing and precision ... access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

GeneSight is designed to help healthcare ... The partnership with jscreen aims to leverage Myriad's genetic testing products and jscreen's education and genetic care programs to reach a broad ...

GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

(NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine, announced its disagreement with UnitedHealthcare's recent policy update. The insurer plans to restrict coverage ...